Transcription profiling of human SUM44 and LCCTam cells reveals ERRgamma mediates Tamoxifen resistance in novel models of invasive lobular breast cancer

ABSTRACT: One-third of all ER+ breast tumors treated with endocrine therapy fail to respond, and the remainder are likely to relapse in the future. Almost all data on endocrine resistance has been obtained in models of invasive ductal carcinoma (IDC). However, invasive lobular carcinomas (ILC) comprise up to 15% of newly diagnosed invasive breast cancers diagnosed each year and, while the incidence of IDC has remained relatively constant during the last 20 years, the prevalence of ILC continues to increase among postmenopausal women. We report a new model of Tamoxifen (TAM)-resistant invasive lobular breast carcinoma cells that provides novel insights into the molecular mechanisms of endocrine resistance. SUM44 cells express ER and are sensitive to the growth inhibitory effects of antiestrogens.

ORGANISM(S): Homo sapiens

SUBMITTER: Rebecca Riggins 

PROVIDER: E-GEOD-12708 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress